KPV
KPV (Lys-Pro-Val) — Alpha-MSH Tripeptide
KPV is the C-terminal tripeptide fragment of alpha-Melanocyte-Stimulating Hormone (α-MSH). It retains the anti-inflammatory potency of the parent molecule without its melanogenic and hormonal side effects. Research focuses primarily on inflammatory bowel disease, wound healing, and anti-inflammatory applications across multiple organ systems.
Mechanism of Action
KPV binds melanocortin receptors (MC1R and MC3R) expressed on immune cells, epithelial cells, and neurons. Receptor activation suppresses NF-κB-mediated pro-inflammatory cytokine production (TNF-α, IL-6, IL-8) and drives anti-inflammatory pathways including IL-10 upregulation.
In the gut, KPV is particularly effective because it is taken up intact by intestinal epithelial cells via the PepT1 transporter — enabling oral bioavailability for gastrointestinal applications. This makes it one of the few peptides where oral dosing is pharmacologically validated for local GI effects.
KPV also activates melanocortin pathways in the CNS, contributing to fever reduction and systemic anti-inflammatory signalling. Its small size (3 amino acids) enables good tissue penetration including topical applications.
Research Evidence
KPV has robust preclinical data for inflammatory bowel conditions (Crohn's disease, ulcerative colitis models) and wound healing. Oral nanoparticle formulations have been developed to improve colonic delivery.
Oral KPV Reduces Colitis in Murine Models via PepT1 Transport
Oral KPV loaded into nanoparticles and administered to DSS-induced colitis mice reduced colonic inflammation, mucosal damage scores, and pro-inflammatory cytokine levels significantly versus controls, establishing oral delivery feasibility.
Typical Research Protocol
For systemic anti-inflammatory effects, SC dosing is preferred. For GI applications (IBD, leaky gut), oral KPV formulated in capsules or blended with BPC-157 is the most relevant delivery approach.
Safety Profile
Reported Side Effects
- Injection site redness (SC)
- Mild skin darkening (possible — MC1R activity)
- Headache (rare)
Contraindications
- Known melanocortin sensitivity
- Pregnancy (insufficient data)
- Active melanoma (MC1R concern)
Published Research
28 indexed PubMed papers reference KPV. The 20 most recent are listed below.
- Host defense peptides as a new drug lead to a strategy for inflammatory bowel disease.
- The Melanocortin System in Inflammatory Bowel Diseases: Insights into Its Mechanisms and Therapeutic Potentials.
- Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats.
- Novel anti-inflammatory and chondroprotective effects of the human melanocortin MC1 receptor agonist BMS-470539 dihydrochloride and human melanocortin MC3 receptor agonist PG-990 on lipopolysaccharide activated chondrocytes.
- Are melanocortin peptides future therapeutics for cutaneous wound healing?
- Structural modification of the tripeptide KPV by reductive "glycoalkylation" of the lysine residue.
- Peptide Receptor-Targeted Fluorescent Probe: Visualization and Discrimination between Chronic and Acute Ulcerative Colitis.
- Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin.
- Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model.
- Modulation of basophil activity: a novel function of the neuropeptide α-melanocyte-stimulating hormone.
- Terminal signal: anti-inflammatory effects of α-melanocyte-stimulating hormone related peptides beyond the pharmacophore.
- Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases.
- Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.
- alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs.
- Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide.
- Inhibitory effects of the peptide (CKPV)2 on endotoxin-induced host reactions.
- Immobilized alpha-melanocyte stimulating hormone 10-13 (GKPV) inhibits tumor necrosis factor-alpha stimulated NF-kappaB activity.
- Three-dimensional structure of the alpha-MSH-derived candidacidal peptide [Ac-CKPV]2.
- alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells.
- New insights into the functions of alpha-MSH and related peptides in the immune system.
Common Research Stacks
Frequently Asked Questions
Does KPV cause skin darkening?
KPV binds MC1R — the same receptor responsible for skin pigmentation. However, KPV's melanogenic activity is far lower than full α-MSH. At research doses, significant skin darkening has not been consistently reported. Those with fair skin or concerns about pigmentation should monitor closely.
How does KPV compare to BPC-157 for gut healing?
KPV and BPC-157 address gut healing through different mechanisms. KPV suppresses immune-mediated inflammation (NF-κB, TNF-α, IL-6) via melanocortin receptors — making it particularly relevant for inflammatory bowel disease (IBD) where immune overactivation is the driver. BPC-157 drives mucosal regeneration and vascularisation through the NO/VEGF pathway. For IBD, KPV is potentially more targeted; for ulcer or injury repair, BPC-157 has stronger evidence.
Can KPV be taken orally?
Yes — KPV is one of the few peptides where oral administration is pharmacologically validated for local GI effects. It is transported intact across intestinal epithelium by the PepT1 dipeptide transporter. Oral capsule or liquid formulations are specifically studied for colitis and IBD indications. For systemic anti-inflammatory effects beyond the gut, SC injection is preferred.
What conditions is KPV being studied for?
Primary research applications include: inflammatory bowel disease (Crohn's disease, ulcerative colitis), wound healing (particularly chronic or inflamed wounds), skin conditions (psoriasis, contact dermatitis), and general systemic anti-inflammatory support. Its melanocortin receptor mechanism is also studied for fever modulation and sepsis research.
Is there a difference between KPV and α-MSH?
α-MSH is the full 13-amino-acid parent peptide. KPV is its C-terminal tripeptide (amino acids 11-13). KPV retains the anti-inflammatory potency of α-MSH via melanocortin receptors but lacks the N-terminal sequence responsible for melanogenesis (skin darkening) and most hormonal effects. This makes KPV safer for chronic use where skin pigmentation is a concern.
Key Research References
- Kannengiesser K et al. (2008). Melanocyte-stimulating hormone peptide inhibits NF-κB activation in gut. Gastroenterology.
- Brzoska T et al. (2008). Alpha-MSH and related tripeptides: biochemistry, anti-inflammatory and protective effects. J Leukoc Biol.
Explore more Recovery research compounds
Browse Recovery →